Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of triple-negative breast cancer (TNBC) patient-derived xenografts (PDX) sensitive and resistant to docetaxel.

ABSTRACT: Transcriptomic profiling of triple-negative breast cancer (TNBC) patient-derived xenografts (PDX) sensitive and resistant to docetaxel.

PROVIDER: PRJNA432960 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic profiling of triple-negative breast cancer (TNBC) patient-derived xenografts (PDX) sensitive and resistant to docetaxel.

Project description:SurePrint G3 Human Gene Expression Microarray v2 was used to obtain gene expression profiles of two different TNBC PDX models sensitive to docetaxel and in the docetaxel resistant TNBC PDX models derived from both initially sensitive.

2019-07-30 | GSE110153 | GEO

Paclitaxel resistance in isogenic PDX

Project description:Tumor heterogeneity and resistance to chemotherapy represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and define actionable targets for next-line treatment. Bulk RNA sequencing were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in downstream approcaches, and their clinical relevance evaluated in publicly available clincial data.

2024-10-01 | GSE265955 | GEO

Transcription profiling of human breast cancer patients sensitive to docetaxel

Project description:These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

2008-06-12 | E-GEOD-350 | biostudies-arrayexpress

Transcription profiling of human breast tumors resistant or sensitive to docetaxel treatment

Project description:This SuperSeries is composed of the following subset Series: GSE349: These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Resistant GSE350 These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

2007-10-26 | E-GEOD-6434 | biostudies-arrayexpress

Epigenetic profiling of docetaxel resistance in Breast Cancer

Project description:Illumina Infinium MethylationEPIC Beadchip was used to obtain DNA methylation profiles across 850000 CpGsites in nine different breast cancer PDX models. Docetaxel resistant and residual disease PDX models were also analyzed

2019-07-18 | GSE110184 | GEO

Src Family Kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer

Project description:Here we quantified tyrosine phosphorylation (pTyr) mediated signaling networks in chemotherapy sensitive (CS) and resistant (CR) TNBC patient derived xenografts (PDX) to gain novel therapeutic insights. We identified Src Family Kinases (SFKs) as potential therapeutic targets in CR TNBC PDXs. Additionally, we performed pTyr analysis on tumor specimens derived from TNBC patients and observed lower prevalence of SFK driven tumors.

2022-10-13 | PXD034154 | Pride

Gene expression data of sensitive, Docetaxel resistant and Paclitaxel resistant MDA-MB-231 Cells

Project description:The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells. RNA isolated from three independent passages of sensitive, Docetaxel and Paclitaxel resistant cell lines and purified using the Qiagen RNeasy Mini Kit. Total RNA was processed and hybridized to Affymetrix Genechip HU133A arrays.

2011-04-22 | E-GEOD-28784 | biostudies-arrayexpress

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [PDX GBM22 orthotopic xenografts]

Project description:Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [PDX GBM22 orthotopic xenografts]

| PRJNA966142 | ENA

Docetaxel treatment upregulates estrogen receptor expression in triple negative breast cancer cells via activating arachidonic acid pathway

Project description:Triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer,accounts for approximately 15% of all cases. TNBC remains challenging due to a lack of effective treatment strategies, which significantly impacts patient survival outcomes. This study investigates a novel combination therapy using Docetaxel, a microtubule depolymerization inhibitor, and Tamoxifen, an estrogen receptor (ER) antagonist, targeting TNBC, as well as elucidate molecular mechanisms. Synergistic effects of Docetaxel with Tamoxifen in TNBC cells were analyzed at SynergyFinder. Their anti-tumor growth effects were determined in vivo using both nude mice and Balb/c mice. RNA-Seq was conducted to analyze the pathways altered by Docetaxel treatment in TNBC cells. We demonstrate that Docetaxel sensitizes TNBC cells to Tamoxifen, despite the typical ER-negative status of TNBC. Here, we reveal that Docetaxel activates the arachidonic acid signaling pathway, leading to increased prostaglandin E2 (PGE2) production and subsequent upregulation of c-Jun phosphorylation, which in turn induces ESR1 expression. This ERα induction enables Tamoxifen to effectively inhibit TNBC cell proliferation. Given the clinical availability of both drugs, our findings propose a promising, translationally feasible combination strategy to address the therapeutic limitations of TNBC, offering a novel approach to improve outcomes for this high-risk patient population.

2025-11-03 | GSE296838 | GEO

Expression data from prostate cancer cell lines C4-2B (docetaxel sensitive) and TaxR (docetaxel resistant) cells

Project description:Prostate cancer C4-2B cells were cultured in docetaxel in a dose-escalation manner. After nine months selection, cells were able to divide freely in 5 nM docetaxel, with a specific sets of genes been deregulated. We performed global gene expression analysis by cDNA microarrays to identify genes responsible for docetaxel resistance in TaxR cells.

2013-08-01 | GSE47040 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data